WeVote
Log In

Bill

DB

Bill

A 1646

Establishes prescription drug pricing disclosure requirements and measures to reduce prescription drug costs.

2024-2025 Regular Session Introduced by Dave Bailey and 1 co-sponsor

New Jersey bill requiring prescription drug pricing transparency and establishing cost-reduction measures to lower medication expenses for residents and state programs.

Introduced in the Assembly, Referred to Assembly Financial Institutions and Insurance Committee
#pharmaceutic
0
WeVote Research Nonpartisan
Bill Summary · A 1646

Legislative bill overview

Bill A 1646 establishes transparency requirements for prescription drug pricing and implements cost-reduction measures within New Jersey. The bill aims to increase public and regulatory visibility into how drug prices are set and paid, potentially creating mechanisms to control costs for consumers and the state's healthcare system.

Why is this important

Prescription drug costs represent a significant portion of healthcare spending for New Jersey residents and state programs like Medicaid. Transparency requirements and cost controls could reduce patient out-of-pocket expenses and state budget pressures, though implementation details would determine actual impact on drug availability and innovation.

Potential points of contention

  • Pharmaceutical industry concerns: Drug manufacturers may argue that price transparency and controls could reduce profit margins needed for research and development of new medications
  • Definition and scope ambiguity: Without seeing specific language, uncertainty exists about which drugs are covered, what pricing metrics are disclosed, and enforcement mechanisms
  • Unintended market effects: Price controls or disclosure requirements could alter drug supply chains, manufacturer decisions to sell in New Jersey, or insurance plan structures in unpredictable ways

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.